Khiron Life Sciences Corp. KHRNF KHRNA is opening a new Zerenia clinic location and a new retail pharmacy in Colombia.
The clinic is located in the city of Bogota, with a maximum annual capacity of 40,000 consults per year.
In addition, the company has opened its first retail pharmacy location within El Ensueño shopping mall. This pharmacy will allow the company to sell medical cannabis products to patients outside its own Zerenia network and dispense high and low THC medical cannabis to insurance companies in the country.
Alvaro Torres, Khiron CEO and director stated, "Khiron has become a clear leader in the Colombian medical cannabis market because of its unique go-to-market strategy, anchored in our Zerenia clinic model. This new expansion within Bogota capitalizes on the Colombian government's decision on mandatory insurance coverage, and we aim to get closer to our patients and insurers, to improve quality of life. With our new retail pharmacy, we aim to be able to offer more access to patients outside our clinic network and to provide a dispensing alternative to insurers, thereby increasing our market leadership within Colombia. As we continue to grow, our leadership is expanding to Latin America and Europe, thanks to our ability to generate evidence, offer high quality products, and create an excellent patient-focused healthcare service that improves quality of life".
Alvaro Torres, CEO of Khiron Life Sciences Corp., will be one of the speakers at the Benzinga Cannabis Capital Conference in Miami. There’s still time to sign up for the event that will host many top names in the cannabis industry. Click here for more info.
Meet the biggest cannabis industry players and make deals that will push the industry forward.
Featuring live company presentations, insider panels, and unmatched access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet.
Join us September 13-14, 2022 at The Palmer House in Chicago, IL.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.